Thermo Fisher Scientific Inc. TMO
NYSE · Healthcare · Medical - Diagnostics & Research
$669.54
Close on Fri, 20 Nov 2026 · market value $248B
What the price is betting on
Priced for a lot to go rightAt $670, the price assumes revenue grows about 13% a year for five years, from $47.4B to about $80.5B by FY2030. That is about twice what analysts expect for the next two years and about four times the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 8.5% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than TMO? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$394
Base
$450
Bull
$512
Today $670
- Bear $394. Cash flow grows 4% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $450. Cash flow grows 6% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $512. Cash flow grows 8% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$48.9B$48B, on the path
- FY2027$55.4B$50.6B, below the path
- FY2028$62.8B$53.8B, below the path
- FY2029$71.1B$57.2B, below the path
- FY2030$80.5B$59.2B, below the path
Each year's revenue at 13% growth from $47.4B in the 12 months to September 2026.
At a glance
Healthcare · Medical - Diagnostics & Research · listed on NYSE
- Revenue, FY2025
- $44.6B
- Growth, 3 years a year
- 3.7%
- Cash margin
- 14%
- Net debt
- $29.3B
- Shares, 3-year change
- −4.3%
- Dividend yield
- 0.3%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.